GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
STX Heavy Industries Co Ltd
KRX:071970
|
KR |
|
Seazen Group Ltd
HKEX:1030
|
CN |
|
Dentium Co Ltd
KRX:145720
|
KR |
|
JCET Group Co Ltd
SSE:600584
|
CN |
|
A
|
Anacortes Mining Corp
XTSX:XYZ
|
CA |
|
S
|
Senheng New Retail Bhd
KLSE:SENHENG
|
MY |
|
H
|
Hongbaoli Group Corporation Ltd
SZSE:002165
|
CN |
|
Haitong Securities Co Ltd
SSE:600837
|
CN |
|
ARSS Infrastructure Projects Ltd
NSE:ARSSINFRA
|
IN |
|
Moury Construct SA
LSE:0NZS
|
BE |
|
Norsk Hydro ASA
OTC:NHYKF
|
NO |
|
Grupo Mateus SA
BOVESPA:GMAT3
|
BR |
|
N
|
Nikki Co Ltd
TSE:6042
|
JP |
|
C
|
Colgate-Palmolive (India) Ltd
NSE:COLPAL
|
IN |
|
M
|
Muthoot Microfin Ltd
NSE:MUTHOOTMF
|
IN |
|
Super House Ltd
NSE:SUPERHOUSE
|
IN |
GI Innovation Inc
Capital Expenditures
GI Innovation Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Capital Expenditures
-₩24.7m
|
CAGR 3-Years
83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Capital Expenditures
-₩331.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-7%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Capital Expenditures
-₩1.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Capital Expenditures
-₩1.2B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Capital Expenditures
-₩33.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-24%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Capital Expenditures
-₩20.7B
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-101%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Capital Expenditures?
Capital Expenditures
-24.7m
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Capital Expenditures amounts to -24.7m KRW.
What is GI Innovation Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 3Y
83%
Over the last year, the Capital Expenditures growth was 96%. The average annual Capital Expenditures growth rates for GI Innovation Inc have been 83% over the past three years .
